What was the overall timeline for Apotex’s ruxolitinib in the US?
Apotex’s ruxolitinib (marketed in the US as Jakafi by the brand owner) is tied to Apotex’s FDA pathway and then to patent-litigation outcomes. The provided information here does not include a specific date-by-date timeline for Apotex’s entry or US approvals, so the exact sequence and dates can’t be reconstructed from the available material.
When would an Apotex ruxolitinib “entry” have happened in the US?
For a generic/similar ruxolitinib product, the US timeline typically depends on:
- FDA approval timing (including whether the product was approved under an Abbreviated New Drug Application or via another pathway), and
- Whether and when relevant Orange Book patents were cleared or blocked via litigation (for example, a 30-month stay, settlement dates, or injunction/lift dates).
However, no US approval or litigation dates for Apotex are included in the information you provided, so I can’t list the exact timing.
Is there a specific “timeline” you want: FDA approval, launch date, or court events?
People asking this question often mean one of these:
- FDA approval date (when the product got marketing authorization in the US),
- “launch”/commercial availability date (when pharmacies could actually dispense it), or
- major court dates (complaint, answers, injunctions, settlements, or patent-expiry milestones).
Tell me which of these you mean and, if possible, share the source text or link you’re working from. With that, I can produce a precise, date-ordered timeline.
What I need to give you an accurate date-by-date timeline
Please provide one of the following:
- A link to the article/court record you’re referencing, or
- The names of the specific Apotex entity (e.g., Apotex Inc. vs Apotex Corp.), plus the product strength(s) and whether you mean “ruxolitinib” broadly or a specific generic/seller listing, or
- The patent(s)/Orange Book listing(s) involved.
Sources: none provided.